Clinical-stage oncology entity Prescient Therapeutics (ASX: PTX) — focused on the development of novel and personalised cancer-related therapies — has released its half-year report for…

Prescient (ASX:PTX) highlights that its latest quarter achievements have strengthened its mark as an evolving player for the next generation of personalised therapies for cancer.

Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) is focused on developing its innovative pipeline in personalised medicine to address significant unmet needs. The company’s development portfolio comprises cell…

Prescient Therapeutics (ASX:PTX), an Australian biotech player developing personalised medicine therapies for cancer, has published its report for the September quarter. The company sees the…

Clinical-stage oncology firm Prescient Therapeutics Limited (ASX:PTX), has provided an upbeat update regarding the encouraging clinical activity of PTX-100, one of the targeted therapies of Prescient. PTX-100…

Prescient Therapeutics (ASX: PTX) has presented exciting new data on CellPryme-A at the 7th Annual CAR-TCR Summit in Boston, MA. The summit is one of the…

Prescient Therapeutics (ASX: PTX) takes a crucial step in advancing its next-generation cell therapy platform, OmniCAR. The clinical-stage oncology player entered into a strategic agreement with The…

Clinical-stage oncology firm Prescient Therapeutics (ASX: PTX) announces a Share Purchase Plan (SPP) to raise AU$8.0 million. Funds raised from the SPP will be used for the…

Clinical-stage oncology firm Prescient Therapeutics (ASX:PTX) is working towards expanding its next-generation cell immunotherapy program. At the same time, Prescient is advancing major clinical programs, PTX-100 and…